Bradykinin: Inflammatory Product of the Coagulation System

Clinical Reviews in Allergy and Immunology

Volumn 51, Issue 2, 2016, Pages 152-161

  Hofman, Zonne ^a   de Maat, Steven ^a   Hack, C Erik ^a   Maas, Coen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angioedema; Bradykinin; D dimer; Factor XII; HAE; Histamine; Plasmin

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; FIBRIN; HEAT SHOCK PROTEIN 90; PLASMIN; PROLINE CARBOXYPEPTIDASE; THROMBIN; AUTACOID; BIOLOGICAL MARKER; PLASMINOGEN;

ANGIONEUROTIC EDEMA; BLOOD CLOTTING; CELL ACTIVATION; DISEASE ACTIVITY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; LEUKOCYTE ACTIVATION; MAST CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANGIOEDEMA; ANIMAL; BLOOD; ENZYME ACTIVATION; IMMUNOLOGY; METABOLISM; NEUTROPHIL;

ANGIOEDEMA; ANIMALS; BIOMARKERS; BLOOD COAGULATION; BRADYKININ; ENZYME ACTIVATION; FACTOR XII; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; MAST CELLS; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLASMINOGEN;

EID: 84987917103     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-016-8540-0     Document Type: Review

References (108)

1. van der Linden PW, Hack CE, Eerenberg AJ, Struyvenberg A, van der Zwan JK (1993) Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 82:1732–1739
2. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al (2014) The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69:868–887
3. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K et al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602–616
4. Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R et al (2015) Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med 277:585–593
5. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B et al (2006) Angioedema without urticaria: a large clinical survey. Can Med Assoc J 175:1065–1070
6. Fields T, Ghebrehiwet B, Kaplan AP (1983) Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol 72:54–60
7. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693–1697
8. Nussberger J, Cugno M, Cicardi M, Agostoni A (1999) Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104:1321–1322
9. Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM et al (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139:1143–1156
10. Oschatz C, Maas C, Lecher B, Jansen T, Björkqvist J, Tradler T et al (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34:258–268
11. Maas C, Govers-Riemslag JWP, Bouma B, Schiks B, Hazenberg BPC, Lokhorst HM et al (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118:3208–3218
12. White-Adams TC, Berny MA, Patel IA, Tucker EI, Gailani D, Gruber A et al (2010) Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost 8:1295–1301
13. van der Meijden PEJ, Munnix ICA, Auger JM, Govers-Riemslag JWP, Cosemans JMEM, Kuijpers MJE et al (2009) Dual role of collagen in factor XII-dependent thrombus formation. Blood 114:881–890
14. Kaplan AP (2010) Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 126:918–925
15. Gösswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygören-Pürsün E et al (2008) Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 121:181–188
16. Dewald G, Bork K (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343:1286–1289
17. Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A et al (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098–1104
18. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G (2011) A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 141:31–35
19. Grumach AS, Stieber C, Veronez CL, Cagini N, Constantino-Silva RN, Cordeiro E et al (2016) Homozygosity for a factor XII mutation in one female and one male patient with hereditary angio-oedema. Allergy 71:119–123
20. Gelincik A, Demir S, Olgaç M, Karaman V, Toksoy G, Çolakoğlu B et al (2015) Idiopathic angioedema with F12 mutation: is it a new entity? Ann Allergy Asthma Immunol 114:154–156
21. Longhurst H, Cicardi M (2012) Hereditary angio-oedema. Lancet 379:474–481
22. Hofman ZLM, Relan A, Hack CE (2014) Hereditary angioedema attacks: local swelling at multiple sites. Clin Rev Allergy Immunol 50:34–40
23. Bygum A, Andersen KE, Mikkelsen CS (2009) Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19:147–151
24. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M et al (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523–531
25. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–541
26. Wu MA, Castelli R (2016) The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity. Clin Chem Lab Med 54:207–214
27. Sinclair D, Smith A, Cranfield T, Lock RJ (2004) Acquired C1 esterase inhibitor deficiency or serendipity? The chance finding of a paraprotein after an apparently low C1 esterase inhibitor concentration. J Clin Pathol 57:445–447
28. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004
29. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–1630
30. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J et al (2005) Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165:1637–1642
31. Maas C (2013) The protease storm of angioedema. J Angioedema 1:18–27
32. Levi M, Hack CE, de Boer JP, Brandjes DP, Büller HR, ten Cate JW (1991) Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 88:1155–1160
33. Braat EA, Dooijewaard G, Rijken DC (1999) Fibrinolytic properties of activated FXII. Eur J Biochem 263:904–911
34. Csuka D, Veszeli N, Imreh É, Zotter Z, Skopál J, Prohászka Z et al (2015) Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 10:132
35. Bork K, Wulff K, Witzke G, Hardt J (2015) Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 70:1004–1012
36. Joseph K, Tholanikunnel BG, Wolf B, Bork K, Kaplan AP (2015) Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. doi:10.1016/j.jaci.2015.07.041
37. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE (2015) Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 70:506–513
38. Bork K, Kleist R, Hardt J, Witzke G (2009) Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 20:325–332
39. van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W (2012) Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 167:472–478
40. Relan A, Bakhtiari K, van Amersfoort ES, Meijers JCM, Hack CE (2012) Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs 26:43–52
41. Joseph K, Tholanikunnel TE, Kaplan AP (2010) Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol 104:50–54
42. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM et al (1997) Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89:3213–3218
43. Nielsen EW, Johansen HT, Høgåsen K, Wuillemin W, Hack CE, Mollnes TE (1996) Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 44:185–192
44. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M (1993) Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 121:38–43
45. Donaldson VH (1993) Plasminogen activation in hereditary angioneurotic edema. J Lab Clin Med 121:13–14
46. Cugno M, Bergamaschini L, Uziel L, Cicardi M, Agostoni A, Jie AF et al (1988) Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency). J Clin Chem Clin Biochem 26:423–427
47. Cullmann W, Kövary PM, Müller N, Dick W (1982) Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin Exp Immunol 49:618–622
48. Mackman N (2009) The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108:1447–1452
49. Fleck RA, Rao LV, Rapaport SI, Varki N (1990) Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 59:421–437
50. Vadivel K, Bajaj SP (2012) Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci (Landmark Ed) 17:2476–2494
51. Maas C, Meijers JCM, Marquart JA, Bakhtiari K, Weeterings C, de Groot PG et al (2010) Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A 107:9083–9087
52. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I et al (1996) Role of tissue factor in embryonic blood vessel development. Nature 383:73–75
53. Ratnoff OD, Colopy JE (1955) A Familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Investig 34:602–613
54. Giangrande PLF (2003) Six characters in search of an author: the history of the nomenclature of coagulation factors. Br J Haematol 121:703–712
55. de Maat S, van Dooremalen S, de Groot PG, Maas C (2013) A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost 109:458–68
56. Iwaki T, Castellino FJ (2006) Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 95:1003–1010
57. Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP (2013) Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol 132:470–475
58. Dobó J, Major B, Kékesi KA, Szabó I, Megyeri M, Hajela K et al (2011) Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One 6:e20036
59. Kiss N, Barabás E, Várnai K, Halász A, Varga LÁ, Prohászka Z et al (2013) Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 149:142–145
60. Olson JD (2015) D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem 69:1–46
61. Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129:307–321
62. Declerck PJ, Gils A (2013) Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 39:356–364
63. Ellis V, Behrendt N, Danø K (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752–12758
64. Goldsmith GH, Saito H, Ratnoff OS (1978) The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. J Clin Invest 62:54–60
65. Lenich C, Pannell R, Gurewich V (1995) Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 74:698–703
66. Pedersen OD, Munkvad S, Gram J, Kluft C, Jespersen J (1993) Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur Heart J 14:785–789
67. Govers-Riemslag JWP, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE et al (2007) The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 5:1896–1903
68. Tanaka A, Suzuki Y, Sugihara K, Kanayama N, Urano T (2009) Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Life Sci 85:220–225
69. Ewald GA, Eisenberg PR (1995) Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 91:28–36
70. Pönitz V, Pritchard D, Grundt H, Nilsen DWT (2006) Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J Thromb Thrombolysis 22:199–203
71. Bozkurt S, Arslan ED, Köse A, Ayrık C, Yılmaz A, Dündar GA (2015) Lingual angioedema after alteplase treatment in a patient with acute ischemic stroke. World J Emerg Med 6:74–76
72. Madden B, Chebl RB (2015) Hemi orolingual angioedema after tPA administration for acute ischemic stroke. West J Emerg Med 16:175–177
73. Correia AS, Matias G, Calado S, Lourenço A, Viana-Baptista M (2015) Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal. J Stroke Cerebrovasc Dis 24:31–40
74. Wallon D, Girardie P, Bombois S, Lucas C (2010) Angioneurotic orolingual oedema following thrombolysis in acute ischaemic stroke. BMJ Case Rep. doi:10.1136/bcr.06.2010.3094
75. Sonny A, Avitsian R, Hussain MS, Elsharkawy H (2015) Angioedema in the neurointerventional suite. J Clin Anesth 27:170–174
76. Scialò C, Strada L, Finocchi C, Gandolfo C, Balestrino M (2015) Angioedema after rt-PA treatment in acute ischemic stroke may be attended by shock and worsening of stroke outcome. Neurol Sci 36:795–796
77. Wu TY, Wei DY, Baker Y, Sharkey B, Frith RW (2014) Asymmetric oro-facial angioedema following alteplase for acute ischaemic stroke. J Clin Neurosci 21:2004–2006
78. Lin SY, Tang S-C, Tsai L-K, Yeh S-J, Hsiao Y-J, Chen Y-W et al (2014) Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. EurJ Neurol 21:1285–1291
79. Lekoubou A, Philippeau F, Derex L, Olaru A, Gouttard M, Vieillart A et al (2014) Audit report and systematic review of orolingual angioedema in post-acute stroke thrombolysis. Neurol Res 36:687–694
80. Yayan J (2013) Onset of orolingual angioedema after treatment of acute brain ischemia with alteplase depends on the site of brain ischemia: a meta-analysis. N Am J Med Sci 5:589–593
81. Foster-Goldman A, McCarthy D (2013) Angioedema from recombinant TPA administration: case report and pathophysiology review. Am J Ther 20:691–693
82. Yayan J (2012) Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase. Int J Gen Med 5:183–186
83. Hurford R, Rezvani S, Kreimei M, Herbert A, Vail A, Parry-Jones AR et al (2015) Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatry 86:520–523
84. de Oliveira DC, Coelho OR, Paraschin K, Ferraroni NR, Zolner RL (2005) Angioedema related to the use of streptokinase. Arq Bras Cardiol 85:131–134
85. Cooper JP, Quarry DP, Beale DJ, Chappell AG (1994) Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 70:592–593
86. Pechlaner C, Knapp E, Wiedermann CJ (2001) Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. Blood Coagul Fibrinolysis An Int J Haemost Thromb 12:491–494
87. de Maat S et al (2016) Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol. doi:10.1016/j.jaci.2016.02.021
88. Frank MM, Sergent JS, Kane MA, Alling DW (1972) Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 286:808–812
89. Blohmé G (1972) Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand 192:293–298
90. Tengborn L, Blombäck M, Berntorp E (2015) Tranexamic acid--an old drug still going strong and making a revival. Thromb Res 135:231–242
91. Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ (2000) Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294:263–269
92. Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M (2014) High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin mediated angioedema due to hereditary c1-inhibitor deficiency. Clin Exp Allergy 44:1503–1514
93. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M (2009) Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 64:254–257
94. Nilsson T, Bäck O (1985) Elevated plasmin-alpha 2-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb Res 40:817–821
95. Bork K, Witzke G, Artmann K, Benes P, Böckers M, Kreuz W (1984) Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria. Arch Dermatol Res 276:375–380
96. Veszeli N, Csuka D, Zotter Z, Imreh É, Józsi M, Benedek S et al (2015) Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 10:156
97. Nauseef WM, Borregaard N (2014) Neutrophils at work. Nat Immunol 15:602–611
98. Brower MS, Harpel PC (1982) Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 257:9849–9854
99. Stuardo M, Gonzalez CB, Nualart F, Boric M, Corthorn J, Bhoola KD et al (2004) Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J Leukoc Biol 75:631–640
100. Araújo RC, Kettritz R, Fichtner I, Paiva AC, Pesquero JB, Bader M (2001) Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol Chem 382:91–95
101. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M et al (1986) Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67:1731–1737
102. Oehmcke S, Mörgelin M, Herwald H (2009) Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 1:225–230
103. Nussberger J, Cugno M, Cicardi M (2002) Bradykinin-mediated angioedema. N Engl J Med 347:621–622
104. Sala-Cunill A, Björkqvist J, Senter R, Guilarte M, Cardona V, Labrador M et al (2014) Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 135:1031–43
105. Proud D, Siekierski ES, Bailey GS (1988) Identification of human lung mast cell kininogenase as tryptase and relevance of tryptase kininogenase activity. Biochem Pharmacol 37:1473–1480
106. Meneghetti MCZ, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA et al (2015) Heparan sulfate and heparin interactions with proteins. J R Soc Interface 12:0589
107. Obtułowicz A, Pirowska M, Dyga W, Czarnobilska E, Wojas-Pelc A (2015) Tryptase and histamine in patients with angioedema due to C1-inhibitor deficiency (Hereditary Angioedema, HAE) and in patients with mastocytosis. Alerg Astma Immunol 20:106–110
108. Lang DM, Sugimoto SL, Curd JG, Christiansen SC, Zuraw BL (1989) High-molecular weight kininogen is cleaved in active erythema multiforme. J Allergy Clin Immunol 83:802–810